Press Release

The BioEcho subsidiary in the biotechnology hub of Boston is a decisive step in the company’s plan to serve a worldwide growing customer base with best-in-class products and services. The company is a specialized solution provider for the extraction and analysis of nucleic acids. BioEcho Life Sciences Inc. will be operational from 1st of September 2022.

BioEcho has developed a novel product reflecting the company belief that even the most routine molecular biology protocols can be improved: the EchoLUTION Cell Culture RNA Kit. The product delivers dedicated solutions to customers committed with expanding fields such as drug discovery, sequencing, and basic research, such as oncology, immunology, and transcriptomics.

BioEcho Receives Growth Equity Investment from Ampersand

The Nucleic Acid Experts – Certified Twice!

BioEcho achieves two important milestones for its quality management: DIN EN ISO 9001:2015 and DIN EN ISO 13485:2016.

DNA extraction from formalin-fixed paraffin-embedded (FFPE) tissues is an essential step when performing downstream applications used in drug development, biomarker investigation, pathology, as well as in clinical diagnostics and cancer research.

The BioEcho Life Sciences R&D department has successfully completed the My Green Lab Certification Program as a Green Level Certified Lab, which is the highest certification level. 

BioEcho announces the grant of two patents for the innovative EchoLUTION technology transforming established nucleic acid extraction procedures.